Perindoprilat is the active diacid metabolite of Perindopril, an angiotensin-converting enzyme (ACE) inhibitor used in cardiovascular therapy. Perindoprilat itself is a dicarboxylic acid and dipeptide derivative that inhibits angiotensin-converting enzyme and contributes substantially to the pharmacological activity of perindopril.
The CAS Number of anhydrous Perindoprilat is 95153-31-4. Its molecular formula is C17H28N2O5 and its molecular weight is 340.4 g/mol. A recognized solid form is Perindoprilat Monohydrate, CAS 1418095-48-3, with molecular formula C17H30N2O6 and molecular weight 358.4 g/mol.
Perindoprilat is structurally related to the ACE inhibitor family and contains multiple defined stereocenters. The stereochemical configuration is important because the biological activity of the molecule depends on its specific three-dimensional configuration. PubChem reports five defined atom stereocenters for Perindoprilat.
Perindoprilat is also encountered as different solid-state forms, including a monohydrate and other solvated forms. Crystallographic research has characterized the monohydrate as a chiral orthorhombic crystal containing one Perindoprilat zwitterion and one water molecule.
Perindoprilat inhibits angiotensin-converting enzyme, also known as peptidyl-dipeptidase A. ACE is responsible for converting angiotensin I into angiotensin II, a potent vasoconstrictor. Inhibition of ACE reduces angiotensin II formation and contributes to vasodilation and reduction of blood pressure.
Perindopril is administered as a prodrug and is converted in the body to Perindoprilat, its pharmacologically active metabolite. This active metabolite is therefore central to the therapeutic action of perindopril-containing medicines.
Perindoprilat is a specialized pharmaceutical intermediate/API-related compound requiring careful control of chemical identity, stereochemical purity, related substances and solid-state form. Because Perindoprilat can occur in hydrated and solvated forms, control of water and solid form can be particularly important during pharmaceutical development.
Analytical characterization can include infrared spectroscopy, chromatographic testing, optical rotation, water determination and impurity profiling. The applicable specifications should correspond to the exact API form being manufactured, especially when distinguishing anhydrous Perindoprilat from Perindoprilat Monohydrate.
Chromatographic methods are appropriate for monitoring Perindoprilat and related substances. Published pharmacopoeial information for the related Perindopril substance specifically identifies Perindoprilat as Perindopril impurity B, demonstrating its relevance in the impurity profile of Perindopril pharmaceutical substances.
For Perindoprilat API itself, assay, impurity limits, water content and other release criteria should be established from the applicable API specification. Numerical values should not be transferred from the Perindopril or Perindopril Erbumine monograph because those are specifications for a different substance.
Perindoprilat is primarily relevant to ACE-inhibitor pharmaceutical development and cardiovascular research. It is the active metabolite responsible for the ACE-inhibitory activity of Perindopril.
Perindoprilat is also used as a reference substance and analytical standard for pharmaceutical quality-control work involving Perindopril and its degradation or metabolite profile.
High-quality Perindoprilat should demonstrate the correct molecular identity, stereochemical configuration and solid-state form. Where the API is supplied as a monohydrate, the hydrate state and corresponding molecular weight must be correctly identified.
For the CMS specification fields below, verified numerical chemical values are provided where authoritative sources support them. Where a universal API release limit could not be verified, the field is marked N/A rather than assigning an unsupported numerical value.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Water Content | NMT 1.0% |